Preclinical Study Linked New Drug to Fat Loss
A new experimental antibody combined with semaglutide reduced lean muscle loss in non-human primate research.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Should medical treatments for obesity prioritize preserving muscle mass while patients lose weight?
iBio released preclinical study data showing that their investigational antibody, IBIO-610, may help preserve muscle mass during weight loss when paired with semaglutide. This combination therapy is in early-stage development and is not yet available for human use.
Why it matters
Preserving lean muscle mass is a key challenge for patients taking weight-loss medications, as significant muscle loss can affect long-term metabolic health. This new approach aims to shift the body's weight-loss composition to favor fat reduction over muscle degradation.
In an eight-week preclinical study of six obese primates per group, researchers observed that subjects receiving a combination of IBIO-610 and semaglutide experienced significantly lower rates of lean mass loss compared to those treated with semaglutide alone.
The players
iBio
A biotechnology company focused on the development of novel antibody treatments for metabolic and inflammatory conditions.
European Association for the Study of Diabetes
A major professional organization dedicated to advancing diabetes research and clinical care through international scientific exchange.
The details
IBIO-610 is an antibody designed to target the Activin E ligand, which normally blocks fat breakdown by signaling through the ALK7-Smad pathway. By inhibiting this signal, the antibody aims to redirect metabolic processes toward burning fat reserves instead of muscle tissue. In the study, a single intravenous dose of the antibody reduced Activin E serum levels by 97% and demonstrated a 33.2-day half-life in the test subjects.
Timeline
October 1, 2026: Data were presented at the EASD Annual Meeting.
October 13, 2026: iBio released the preclinical study results.
First half of 2027: iBio plans to begin first-in-human studies.
Health Landscape
This development follows a pattern set by the rapid expansion of GLP-1 receptor agonist therapies, attempting to address the documented clinical challenge of muscle wasting during weight loss. The field is currently shifting toward identifying combination therapies that maintain metabolic health while effectively reducing adipose tissue.
It is important to understand that these findings are preclinical and do not yet apply to human medical care or current prescription options. Discuss any concerns regarding muscle mass maintenance or weight-loss side effects during a consultation with your physician.
The takeaway
Maintaining lean muscle mass is a critical factor for long-term health when undergoing weight-loss treatments. As new research emerges, keep track of clinical trial updates and maintain an open conversation with your healthcare team about your specific metabolic and body composition goals.
What happens next
iBio plans to initiate the first human trials for the antibody in the first half of 2027.
Further reading
For more on managing body composition during medical weight management, visit our Weight Loss section.
Live Poll
Should medical treatments for obesity prioritize preserving muscle mass while patients lose weight?
